23 May 2013
Keywords: ph, iii, silenor, data, confirms, positive, package
Article | 19 May 2008
The USA's Somaxon Pharmaceuticals has reported strong data from three Phase III clinical trials of Silenor (doxepin HCl) for insomnia ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 June 2008
22 May 2013
© 2013 thepharmaletter.com